U.S. DEPARTMENT OF DEFENSE AIDED BY IBM, UNITED DEVICES AND ACCELRYS IN SEARCH FOR SMALLPOX CURE
Smallpox Research Grid Project to link more than two million computers
ARMONK, N.Y., AUSTIN, TEXAS, and SAN DIEGO, CA, February 5, 2003 - IBM, United Devices and Accelrys today announced a project supporting a global research effort that is focused on the development of new drugs that could potentially combat the smallpox virus post infection. The project will be powered through a massive computing "Grid" that will enable millions of computer owners worldwide to contribute idle computing resources with the goal of developing a wide collection of potential anti-smallpox drugs.
Results from the Smallpox Research Grid Project will be delivered to the United States Department of Defense's Office of the Secretary of Defense.
According to the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), there is currently no specific treatment for smallpox post infection, and the only prevention is vaccination; however, routine inoculation was discontinued following the WHO effort to eradicate smallpox. The Smallpox Research Grid Project will provide leading screening researchers at Oxford and Essex Universities in the UK and smallpox experts at the Robarts Research Institute, Sloan-Kettering Cancer Center and The University of Western Ontario with the computing horsepower needed to identify new anti-viral drugs.
The Smallpox Research Grid Project is based on technologies and services from IBM, United Devices, Accerlys and Evotec OAI. These commercially available technologies and services are currently used by many pharmaceutical and biotechnology drug companies to improve and accelerate their drug discovery and development processes. An emerging technology called Grid computing allows researchers to pool computing resources such as processing, network bandwidth and storage capacity, for large research projects.
Through the Smallpox Research Grid Project, potentially more than two million personal computers will be linked to create a massive virtual supercomputer delivering a peak processing power of over 1,100 teraflops. That is more than 30 times the power of today's fastest supercomputer as listed at Top500.org. The project employs computational chemistry to analyze chemical interactions between a library of 35 million potential drug molecules and several protein targets on the smallpox virus in the search for an effective anti-viral drug to treat smallpox post-infection.
"IBM and our partners encourage computer owners worldwide to join in and donate their spare processing power for this worthwhile project to develop a new generation of drugs to combat smallpox," said Tom Hawk, general manager, Grid computing for IBM. "Grid computing is poised to launch a revolution in businesses, with life sciences being one of the key areas that will benefit through faster and more efficient drug modeling and development."
Individuals can participate in the Smallpox Research Grid Project by downloading a screensaver at www.grid.org. The screensaver will unobtrusively donate the computer's idle processing power and link it into a worldwide Grid that will act as a virtual supercomputer capable of analyzing billions of molecules in a fraction of the time it would take in a laboratory. Once processing is complete, the program will send results back to United Devices' data center, powered by an IBM infrastructure, and will request new data to analyze. The new data will then be worked on by the individual machine and the results returned the next time the computer user connects to the Internet.
This project falls under the PatriotGrid category of research projects at www.grid.org. PatriotGrid is the world's first public research Grid dedicated specifically to counter bio-terrorism. Participants who sign up at www.grid.org will be able to take an active role in all research projects that fall into this category.
"We've had great success using our massive Global MetaProcessor Grid to target anthrax and cancer research," said United Devices CEO Ed Hubbard. "Helping to identify inhibitors for these targets that could lead to a cure for smallpox in this time frame is only possible using leading applications, an existing infrastructure and a proven grid solution. We're extremely proud to take part in this effort."
Technology and Partners
The Smallpox Research Grid Project is enabled through the expertise, financial and technical capabilities of a number of businesses and educational institutions. These include:
- United Devices - United Devices, a market leader in secure Grid solutions, is coordinating all aspects of the project. United Devices' Global MetaProcessor platform will aggregate the idle power of participating PCs, servers and workstations into its existing worldwide Grid capable of running a wide range of scientific and high-performance computing applications.
- IBM - The Smallpox Research Grid Project is powered by an IBM infrastructure, which includes IBM eServer p690s and IBM's Shark Enterprise Storage Server running DB2 database software. United Devices' Global MetaProcessor Platform uses DB2 exclusively as its host database system. DB2 will handle 15 million SQL queries a day as it manages all aspects of data provided by the approximately two million personal computers analyzing billions of virtual drug screens. Technology in the Smallpox Research Grid Project is an example of one of the ten commercial Grid offerings IBM announced last week. Specifically, it's an Analytics Acceleration Grid, an offering for the Life Sciences industry.
- Accelrys - Accelrys, one of the world's leading software developers in life sciences, is providing the high-throughput docking and scoring software used to screen compounds for the Smallpox Research Grid Project in silico. Accelrys' LigandFit uses a three-dimensional model to analyze molecular data. Using LigandFit, scientists and researchers can accurately predict and prioritize the suitability of potential lead drug candidates for subsequent experimentation and drug development.
- Evotec OAI - An outsourcing service provider for the drug discovery and development process, Evotec OAI has provided its drug modeling expertise to identify and define active sites.
- Leading Universities and Research Institutes - The University of Oxford, assisted by researchers at Essex University and the Robarts Research Institute, has prepared the targets for use with Accelrys' LigandFit and has contributed its large molecular library to the project. The project at the university and research level is led by Dr. Grant McFadden, scientist at Robarts Research Institute and graduate chair of the department of microbiology and immunology at The University of Western Ontario; Dr. Stewart Shuman, Memorial Sloan Kettering Cancer Research; Professor Graham Richards, chairman of the chemistry department at the University of Oxford, and Professor Chris Reynolds, Department of Biological Sciences at Essex at Essex University.
- United States Army Medical Research Institute of Infectious Diseases - They will manage the project for the Department of Defense and will be one of the institutions to further process the most promising drug-like molecular candidates with the goal of developing them to help combat the use of smallpox as a bioterrorist threat or a military weapon.
"Through our donation of technology and scientific expertise, we hope to contribute to the elimination of smallpox as a potential weapon of mass destruction," said Dr. Scott Kahn, chief science officer of Accelrys. "We're excited to partner with these top technology and bioresearch organizations in the fight against terror."
About IBM
IBM is the world's largest information technology company, with 80 years of leadership in helping businesses innovate. IBM Life Sciences brings together IBM resources, from research, services and e-business expertise to data and storage management and high-performance computing, to offer new solutions for the healthcare and life sciences markets. For more information about IBM, visit www.ibm.com. For more information about IBM Life Sciences, visit http://www.ibm.com/lifesciences. For more information about IBM's Grid computing business, visit www.ibm.com/grid.
About United Devices
United Devices is the market leader in secure grid solutions. United Devices' MetaProcessor platform is used to aggregate compute resources on a network to create an enterprise grid capable of running a wide range of high-performance computing applications in life sciences, geosciences, financial services, and other industries. The company also operates the world's largest Grid for grand scale research that consists of more than 2 million devices. For more information on secure grid solutions, visit the United Devices Web site www.ud.com. To volunteer your idle compute power, visit www.grid.org.
About Accelrys Inc.
Accelrys is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists, and materials scientists for product design, drug discovery, and development. Accelrys' platform technology and consulting services enable enterprise-wide solutions tailored to today's leading research organizations. The company's two main centers of excellence are in San Diego, and Cambridge, UK. These centers combine research and product development with facilities to support significant collaborative projects. Accelrys is a subsidiary of Pharmacopeia, Inc. (NASDAQ: PCOP).
About Oxford University
The University of Oxford has more academic staff working in world-class research departments than any other UK university. The Oxford University Chemistry Department is the largest in the western world, with more Chemistry graduates and more students with doctorates being trained at Oxford than at any university in the USA or Europe. The Smallpox Research Grid Project follows in the footsteps of the universally acclaimed cancer screen saver project (see www.chem.ox.ac.uk/curecancer.html) and the anthrax project (see www.chem.ox.ac.uk/anthrax/), which have been running from the Department.
Voor meer informatie
IBM Nederland N.V.
Etta Pouw
Communications
Johan Huizingalaan 761
1066 VH Amsterdam
Tel: 020 513 4228
Fax: 020 617 7600